ArticlePloS one2021
Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- A Scoping Systematic Review of Cannabis Use in Endometriosis.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Article
- Cannabidiol and ∆9-Tetrahydrocannabinol in Endometriosis: A Literature Review on Therapeutic Applications and Mechanisms.JBRA assisted reproduction · 2026Review
- Endometriosis: An Immunologist's Perspective.International journal of molecular sciences · 2025Review
- 'In the weeds': navigating the complex concerns, challenges and choices associated with medicinal cannabis consumption for endometriosis.Reproduction & fertility · 2025Article
- Optimization and Evaluation ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Cannabis use in endometriosis: the patients have their say-an online survey for German-speaking countries.Archives of gynecology and obstetrics · 2024Article
- Evaluating the Current Evidence for the Efficacy of Cannabis in Symptom Management of Endometriosis-Associated Pain.Integrative medicine reports · 2024Review
- Endometriosis: Improvements and challenges in diagnosis and symptom management.Cell reports. Medicine · 2024Review
- ΔCardiovascular toxicology · 2023Article
- "A glimmer of hope" - Perceptions, barriers, and drivers for medicinal cannabis use amongst Australian and New Zealand people with endometriosis.Reproduction & fertility · 2023Article
- Article
- Symptom tracking in endometriosis using digital technologies: Knowns, unknowns, and future prospects.Cell reports. Medicine · 2023Review
- Co-Dispersion Delivery Systems with Solubilizing Carriers Improving the Solubility and Permeability of Cannabinoids (Cannabidiol, Cannabidiolic Acid, and Cannabichromene) fromPharmaceutics · 2023Article
- Role of the endocannabinoid system in the pathophysiology of endometriosis and therapeutic implications.Journal of cannabis research · 2022Review
- Endometriosis and Cannabis Consumption During the COVID-19 Pandemic: An International Cross-Sectional Survey.Cannabis and cannabinoid research · 2022Article
- Molecular and Biochemical Mechanism of Cannabidiol in the Management of the Inflammatory and Oxidative Processes Associated with Endometriosis.International journal of molecular sciences · 2022Article
- The experiences of endometriosis patients with diagnosis and treatment in New Zealand.Frontiers in global women's health · 2022Article
- Comprehensive endometriosis care: a modern multimodal approach for the treatment of pelvic pain and endometriosis.Therapeutic advances in reproductive healthReview
- Relief in Gastrointestinal Symptoms with Medical Marijuana Over 1 Year.Medical cannabis and cannabinoidsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of cannabis for symptoms of endometriosis was investigated utilising retrospective archival data from Strainprint Technologies Ltd., a Canadian data technology company with a mobile phone application that tracks a range of data including dose, mode of administration, chemovar and their effects on various self-reported outcomes, including pelvic pain.
methodsA retrospective, electronic record-based cohort study of StrainprintTM users with self-reported endometriosis was conducted. Self-rated cannabis efficacy, defined as a function of initial and final symptom ratings, was investigated across the included symptom clusters of cramps, pelvic pain, gastrointestinal pain, nausea, depression, and low libido. Cannabis dosage form, dose and cannabinoid ratio information was also recorded.
resultsA total number of 252 participants identifying as suffering endometriosis recorded 16193 sessions using cannabis between April 2017 and February 2020. The most common method of ingestion was inhalation (n = 10914, 67.4%), with pain as the most common reported symptom being treated by cannabis (n = 9281, 57.3%). Gastrointestinal symptoms, though a less common reason for cannabis usage (15.2%), had the greatest self-reported improvement after use. Inhaled forms had higher efficacy for pain, while oral forms were superior for mood and gastrointestinal symptoms. Dosage varied across ingestion methods, with a median dose of 9 inhalations (IQR 5 to 11) for inhaled dosage forms and 1 mg/mL (IQR 0.5 to 2) for other ingested dosage forms. The ratio of THC to CBD had a statistically significant, yet clinically small, differential effect on efficacy, depending on method of ingestion.
conclusionsCannabis appears to be effective for pelvic pain, gastrointestinal issues and mood, with effectiveness differing based on method of ingestion. The greater propensity for use of an inhaled dosage delivery may be due to the rapid onset of pain-relieving effects versus the slower onset of oral products. Oral forms appeared to be superior compared to inhaled forms in the less commonly reported mood or gastrointestinal categories. Clinical trials investigating the tolerability and effectiveness of cannabis for endometriosis pain and associated symptoms are urgently required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.